MedPath

NOE-105

Generic Name
NOE-105

Efficacy and Safety of Gemlapodect (NOE-105) in Adults and Adolescents With Tourette Syndrome

Phase 2
Recruiting
Conditions
Tourette Syndrome
Interventions
Drug: Placebo
First Posted Date
2024-03-18
Last Posted Date
2025-05-15
Lead Sponsor
Noema Pharma AG
Target Recruit Count
180
Registration Number
NCT06315751
Locations
πŸ‡ͺπŸ‡Έ

Noema TTS-201 Site #15, Burgos, Spain

πŸ‡ͺπŸ‡Έ

Noema TTS-201 Site #27, Madrid, Spain

πŸ‡ͺπŸ‡Έ

Noema TTS-201 Site #17, Oviedo, Spain

and more 33 locations

A 10-week Efficacy Study of NOE-105 in Childhood Onset Fluency Disorder (Orpheus)

Phase 2
Completed
Conditions
Childhood-Onset Fluency Disorder
Interventions
Drug: Placebo
First Posted Date
2022-10-18
Last Posted Date
2024-03-13
Lead Sponsor
Noema Pharma AG
Target Recruit Count
75
Registration Number
NCT05583955
Locations
πŸ‡¦πŸ‡Ί

Noema Investigator site, Sydney, New South Wales, Australia

A Study to Evaluate The Effects of RO5545965 in Participants With Negative Symptoms of Schizophrenia Treated With Antipsychotics

Phase 1
Completed
Conditions
Schizophrenia
Interventions
Drug: Placebo
First Posted Date
2016-07-06
Last Posted Date
2017-06-07
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
33
Registration Number
NCT02824055
Locations
πŸ‡ΊπŸ‡Έ

CNS Network, Garden Grove, California, United States

πŸ‡ΊπŸ‡Έ

St Louis Clinical Trials, Saint Louis, Missouri, United States

πŸ‡ΊπŸ‡Έ

Parexel California Clinical Trials Medical Group, Glendale, California, United States

A Study of the Safety, Tolerability and Pharmacokientics of RO5545965 in Patients With Schizophrenia on Risperidone

Phase 1
Completed
Conditions
Schizophrenia
Interventions
First Posted Date
2013-12-24
Last Posted Date
2016-11-02
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
32
Registration Number
NCT02019329

A PET Study With RO5545965 in Healthy Male Volunteers

Phase 1
Completed
Conditions
Schizophrenia
Interventions
First Posted Date
2013-08-14
Last Posted Date
2016-11-02
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
9
Registration Number
NCT01923025

A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO5545965 in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy Volunteer
Interventions
Drug: placebo
First Posted Date
2013-05-29
Last Posted Date
2016-11-02
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
44
Registration Number
NCT01864226

A Study of Safety, Pharmacokinetics (Including Food Effect) And Pharmacodynamics of RO5545965 in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy Volunteer
Interventions
Drug: Placebo
First Posted Date
2012-10-22
Last Posted Date
2016-11-02
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
53
Registration Number
NCT01711801
Β© Copyright 2025. All Rights Reserved by MedPath